ISRCTN27362692 https://doi.org/10.1186/ISRCTN27362692

Intranasal zolmitriptan is effective and well tolerated in acute cluster headache

Submission date	Recruitment status	[_] Prospectively registered
14/02/2006	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
23/02/2006	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
06/08/2008	Signs and Symptoms	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Peter Goadsby

Contact details
Institute of Neurology
University College London
London
United Kingdom
WC1N 3BG

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
ZINCH-1

Study information

Scientific Title

Acronym
ZINCH

Study objectives
Zolmitriptan intranasal is more effective than placebo in the treatment of acute cluster headache.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics approval received from the National Hospital for Neurology and Neurosurgery Ethics Committee on the 8th May 2003 (ref: 02/N031).

Study design
Randomised, placebo-controlled, double-blind cross-over trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Cluster headache

Interventions
Zolmitriptan nasal spray versus placebo.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Zolmitriptan

Primary outcome measure
Proportion of patients who have taken active drug with headache relief at 30 minutes.

Secondary outcome measures
Pain free at 30 minutes.

Overall study start date
01/09/2003

Completion date
01/01/2005

Eligibility

Key inclusion criteria
Cluster headache with attacks longer than 45 minutes.

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
90

Key exclusion criteria
Contraindications to zolmitriptan in participating countries.

Date of first enrolment
01/09/2003

Date of final enrolment
01/01/2005

Locations

Countries of recruitment
England

Germany

Italy

United Kingdom

Study participating centre

Institute of Neurology
London
United Kingdom
WC1N 3BG

Sponsor information

Organisation
AstraZeneca (UK)

Sponsor details
Alderley Park
Macclesfield
United Kingdom
SK10 2NA

Sponsor type
Industry

ROR
https://ror.org/04r9x1a08

Funder(s)

Funder type
Industry

Funder Name
AstraZeneca (UK)

Alternative Name(s)
AstraZeneca PLC, Pearl Therapeutics

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/11/2006		Yes	No